With the landmark trial against Merck adjourned until September 2025, new evidence suggests the vaccine manufacturer may have deliberately misrepresented the necessity of mass HPV vaccination.
With the landmark trial against Merck adjourned until September 2025, new evidence suggests the vaccine manufacturer may have deliberately misrepresented the necessity of mass HPV vaccination.